PerpEquities

Abivax S.A. (ABVX) financials

NASDAQ · Healthcare · Biotechnology · 80 employees · CEO Marc de Garidel

Price
$86.59 -2.77%
Market cap
$7.58B
Enterprise value
€6.41B
Last report
Q2 '26 filed 2026-09-21
Next report
2026-12-21
Revenue (TTM)–– vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)–– vs a year agoOperating income –
Net income (TTM)–– vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)–– vs a year agoCapex –
Diluted EPS (TTM)–– vs a year agoSum of the last 4 quarters
Net cash€409M+1,833.1% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
$7.58B
EV €6.41B
Revenue
–
Trailing 12 months
Revenue growth
–
Next fiscal year
Profit margin
–
Net income / revenue, TTM
P/E
-16.5×
P/S
-3,368.0×
Price / sales, TTM
EV / EBITDA
-23.0×
TTM
Free cash flow
–
Trailing 12 months
Net income
–
Trailing 12 months
Revenue estimate
–
Next fiscal year
Earnings
2026-12-21
Dividend
–
No dividend

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Diluted share count up 25.6% in a year79.6M diluted shares in Q2 '26, 63.4M a year earlier.
  • Net cash €409MCash + short-term investments €411M, debt incl. leases €1.21M; a year ago net debt €23.6M.

Last quarter: Q2 '26

Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q2 '26Year agoChange
Revenue€0€0–
Operating income-€84.1M-€46.5M-80.9%
Net income-€117M-€48.4M-142.6%
Diluted EPS-€1.47-€1.59+7.5%
Operating cash flow-€52M-€33.3M-55.9%
Capex€112K€19K+489.5%
Free cash flow-€52.1M-€33.4M-56.2%
R&D€58.3M€38.6M+51.0%
Stock-based compensation€16.8M€6.33M+165.3%

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement
Free cash flow
–
Returned to shareholders / FCF
–

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)-16.5×––
EV / EBITDA-23.0×––
EV / Sales-3,176.2×––
Price / FCF-46.0×––
Price / Book16.9×11.1×2.1× – 20.6×
FCF yield-2.2%-27.5%-40.0% – -2.0%
Return on invested capital-61.0%-73.9%-119.8% – -44.7%
Return on equity-85.9%-318.4%-844.9% – -73.9%

Analysts

Consensus target $156.00 (+80.2%)
range $118.00 – $180.00 · rating Buy

Strong buy0
Buy12
Hold1
Sell0
Strong sell0

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpenBalance sheetCash, investments, assets, debt, liabilities and equityOpenCash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in EUR as reported; price and market cap in USD.